New York, Feb 3, 2026, 07:20 (EST) — Premarket
- Shares of Liminatus Pharma surged roughly 29% in early premarket action.
- The stock jumped sharply in Monday’s after-hours, underscoring the wild swings among low-priced shares.
- Investors are zeroed in on when the company will resolve its Nasdaq minimum bid-price deficiency.
Shares of Liminatus Pharma, Inc. (LIMN) jumped 29.4% to $0.74 during premarket trading Tuesday, on volume of roughly 5.3 million shares. The firm’s market cap stood near $15.5 million.
The stock surged 64.6% in after-hours trading Monday, climbing to $0.94 following the 4 p.m. close, after finishing the regular session at $0.57.
The shares have lingered below $1, a critical cutoff for a small company’s Nasdaq listing. Currently trading at 74 cents, the stock remains about a third below that key level.
Liminatus revealed in a Jan. 26 filing that it got a Nasdaq notice on Jan. 15 after its stock closed below $1 for 30 straight business days. The company now has until July 14, 2026, to close at $1 or higher for at least 10 consecutive business days to meet listing standards, the filing states. Liminatus said it is “working diligently to regain compliance” but didn’t guarantee success. Securities and Exchange Commission
Nasdaq rules allow for a reverse stock split, which cuts the number of shares outstanding and boosts the price per share. This move doesn’t alter the company’s total value by itself, but it can influence trading behavior and investor sentiment.
Liminatus, a pre-clinical-stage immuno-oncology firm, focuses on immune-modulating cancer therapies. The company is headquartered in La Palma, California, according to its profile.
The price action is all over the place. The stock touched 94 cents in after-hours trading Monday, only to slide back down to the mid-70-cent range before Tuesday’s market open — a clear sign that extended-hours sessions can amplify volatility.
The risk here: the rally could fizzle when regular trading kicks in, pushing shares below the threshold needed to clear the path to $1. If the company fails to fix the deficiency, delisting becomes a real threat, potentially drying up liquidity and locking out certain investors.
Traders will be eyeing if the stock can maintain its gains post-opening bell, as well as any company filings or corporate moves that shed light on its strategy to meet the Nasdaq minimum bid-price rule before the July 14 deadline.
